In this context, the development of Artificial Pancreas (AP) systems, composed of a Continuous Glucose Monitoring (CGM) sensor fitted with a pump to deliver insulin, is becoming the standard for T1D treatment (2, 3). This evidence concerns the gene INS and type 1 diabetes mellitus.